377 related articles for article (PubMed ID: 9815535)
61. A phase I study of swainsonine in patients with advanced malignancies.
Goss PE; Baptiste J; Fernandes B; Baker M; Dennis JW
Cancer Res; 1994 Mar; 54(6):1450-7. PubMed ID: 8137247
[TBL] [Abstract][Full Text] [Related]
62. Phase I study of the duocarmycin semisynthetic derivative KW-2189 given daily for five days every six weeks.
Alberts SR; Erlichman C; Reid JM; Sloan JA; Ames MM; Richardson RL; Goldberg RM
Clin Cancer Res; 1998 Sep; 4(9):2111-7. PubMed ID: 9748127
[TBL] [Abstract][Full Text] [Related]
63. Phase I bioavailability and pharmacokinetic study of hexamethylene bisacetamide (NSC 95580) administered via nasogastric tube.
Ward FT; Kelley JA; Roth JS; Lombardo FA; Weiss RB; Leyland-Jones B; Chun HG
Cancer Res; 1991 Apr; 51(7):1803-10. PubMed ID: 2004365
[TBL] [Abstract][Full Text] [Related]
64. A phase I clinical and pharmacokinetic trial of hepsulfam.
Ravdin PM; Havlin KA; Marshall MV; Brown TD; Koeller JM; Kuhn JG; Rodriguez G; Von Hoff DD
Cancer Res; 1991 Dec; 51(23 Pt 1):6268-72. PubMed ID: 1933887
[TBL] [Abstract][Full Text] [Related]
65. Clinical investigation of a cytostatic calcium influx inhibitor in patients with refractory cancers.
Kohn EC; Reed E; Sarosy G; Christian M; Link CJ; Cole K; Figg WD; Davis PA; Jacob J; Goldspiel B; Liotta LA
Cancer Res; 1996 Feb; 56(3):569-73. PubMed ID: 8564973
[TBL] [Abstract][Full Text] [Related]
66. Phase I and clinical pharmacology trial of 502U83 using a monthly single dose schedule.
Von Hoff DD; Kuhn JG; Havlin KA; Langevin AM; Brown TD; Weiss GR; Turner JN; Purvis J; Lucas VS; Bair KW
Cancer Res; 1990 Dec; 50(23):7496-500. PubMed ID: 2253197
[TBL] [Abstract][Full Text] [Related]
67. A phase I dose-escalation study of the immunocytokine EMD 521873 (Selectikine) in patients with advanced solid tumours.
Gillessen S; Gnad-Vogt US; Gallerani E; Beck J; Sessa C; Omlin A; Mattiacci MR; Liedert B; Kramer D; Laurent J; Speiser DE; Stupp R
Eur J Cancer; 2013 Jan; 49(1):35-44. PubMed ID: 22918078
[TBL] [Abstract][Full Text] [Related]
68. Phase I evaluation and pharmacokinetics of tiazofurin (2-beta-D-ribofuranosylthiazole-4-carboxamide, NSC 286193).
Melink TJ; Von Hoff DD; Kuhn JG; Hersh MR; Sternson LA; Patton TF; Siegler R; Boldt DH; Clark GM
Cancer Res; 1985 Jun; 45(6):2859-65. PubMed ID: 3986813
[TBL] [Abstract][Full Text] [Related]
69. Phase 1 clinical evaluation of recombinant interleukin-2.
Kohler PC; Hank JA; Moore KH; Storer B; Bechhofer R; Sondel PM
Prog Clin Biol Res; 1987; 244():161-72. PubMed ID: 3498945
[TBL] [Abstract][Full Text] [Related]
70. Phase I and pharmacokinetic study of the P-glycoprotein modulator dexniguldipine-HCL.
Nuessler V; Scheulen ME; Oberneder R; Kriegmair M; Goebel KJ; Rathgeb F; Wurst W; Zech K; Wilmanns W
Eur J Med Res; 1997 Feb; 2(2):55-61. PubMed ID: 9085015
[TBL] [Abstract][Full Text] [Related]
71. Phase I trial of menogaril administered as an intermittent daily infusion for 5 days.
Sigman LM; Van Echo DA; Egorin MJ; Whitacre MY; Aisner J
Cancer Treat Rep; 1986 Jun; 70(6):721-5. PubMed ID: 2942244
[TBL] [Abstract][Full Text] [Related]
72. A phase I study of MN-029 (denibulin), a novel vascular-disrupting agent, in patients with advanced solid tumors.
Ricart AD; Ashton EA; Cooney MM; Sarantopoulos J; Brell JM; Feldman MA; Ruby KE; Matsuda K; Munsey MS; Medina G; Zambito A; Tolcher AW; Remick SC
Cancer Chemother Pharmacol; 2011 Oct; 68(4):959-70. PubMed ID: 21305290
[TBL] [Abstract][Full Text] [Related]
73. Clinical pharmacology of hepatic arterial infusions of 5-bromo-2'-deoxyuridine.
Ensminger WD; Walker SC; Stetson PL; Wagner JG; Knol JA; Lawrence TS; Andrews JC
Cancer Res; 1994 Apr; 54(8):2121-4. PubMed ID: 8174116
[TBL] [Abstract][Full Text] [Related]
74. Phase I trial of escalating pentoxifylline dose with constant dose thiotepa.
Dezube BJ; Eder JP; Pardee AB
Cancer Res; 1990 Nov; 50(21):6806-10. PubMed ID: 2119882
[TBL] [Abstract][Full Text] [Related]
75. Phase I clinical and pharmacological study of liposome-entrapped cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum(II).
Perez-Soler R; Lopez-Berestein G; Lautersztain J; al-Baker S; Francis K; Macias-Kiger D; Raber MN; Khokhar AR
Cancer Res; 1990 Jul; 50(14):4254-9. PubMed ID: 2364384
[TBL] [Abstract][Full Text] [Related]
76. Phase I clinical investigation of 9,10-anthracenedicarboxaldehyde bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride with correlative in vitro human tumor clonogenic assay.
Alberts DS; Mackel C; Pocelinko R; Salmon SE
Cancer Res; 1982 Mar; 42(3):1170-5. PubMed ID: 7037174
[TBL] [Abstract][Full Text] [Related]
77. Phase I evaluation and clinical pharmacology of tricyclic nucleoside 5'-phosphate using a weekly intravenous regimen.
Schilcher RB; Haas CD; Samson MK; Young JD; Baker LH
Cancer Res; 1986 Jun; 46(6):3147-51. PubMed ID: 3698029
[TBL] [Abstract][Full Text] [Related]
78. A preliminary Phase I trial of partially purified interferon-gamma in patients with cancer.
Sherwin SA; Foon KA; Abrams PG; Heyman MR; Ochs JJ; Watson T; Maluish A; Oldham RK
J Biol Response Mod; 1984 Dec; 3(6):599-607. PubMed ID: 6439828
[TBL] [Abstract][Full Text] [Related]
79. Phase I trial of chlorozotocin.
Gralla RJ; Tan CT; Young CW
Cancer Treat Rep; 1979 Jan; 63(1):17-20. PubMed ID: 154363
[TBL] [Abstract][Full Text] [Related]
80. Phase I trial of extracellular adenosine 5'-triphosphate in patients with advanced cancer.
Haskell CM; Wong M; Williams A; Lee LY
Med Pediatr Oncol; 1996 Sep; 27(3):165-73. PubMed ID: 8699994
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]